Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 9/14 cls
Alnylam (ALNY) Cantor Fitzgerald Pamela Bassett Upgrade Buy (from hold) 4% $27.99
Bassett raised her target to $32 from $20 after ALNY formed Regulus, a JV with Isis (ISIS) to discover, develop and commercialize miRNA therapeutics. She believes ALNY's consolidation of its miRNA technology platform into the JV will strengthen ALNY's position in RNAi and allow the company's development and licensing programs to undergo a robust period of expansion (see "Make Microlove, Not War," A9).
Amylin (AMLN) Lazard Matthew Osborne Upgrade Buy (from hold) 2% $49.02
Osborne set a target of $58. He expects high demand from endocrinologists for

Read the full 1175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers